PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/PRIVATE BETA — FOUNDER ACCESS ONLY/INVESTORS PERMANENTLY EXCLUDED/VERIFIED FOUNDERS ONLY/
← Fund Intelligence
DOSSIER // VERIFIED INTEL

Andreessen Horowitz Bio + Health

Menlo Park, CAANDREESSEN-HOROWITZ-BIO-HEALTH
0
Truth Cards
0
Partners Rated
—
Avg Score
Get Access
Access Level
◈ Truth Cards
0 VERIFIED
◈

No verified intel yet.
Be the first founder to leave a truth card.

Request Founder Access →
Dossier Summary

a16z's life sciences practice investing across biotech, digital health, and health system transformation.

Classification
Slugandreessen-horowitz-bio-health
HQMenlo Park, CA
Stage FocusPrimarily Series A to growth stage investments in biotech…
Intel StatusAccepting submissions
🔥 BERNIE'S HOT TAKE

A16z Bio brings serious firepower and deep pockets, but you're getting the full Andreessen treatment - meaning lots of platform resources but also high expectations and board oversight. They're genuinely helpful on business model design and scaling challenges, especially if you're building something that intersects tech and bio. The partners actually know healthcare, which is rarer than you'd think. Downside: they're not afraid to bring in new management if things go sideways, and their brand attracts competitor attention early.

KEY TAKEAWAYS
  • —Best for: Tech-enabled healthcare companies ready to scale fast
  • —Watch out for: High performance expectations and potential management changes
  • —Known for: Deep healthcare expertise and massive platform resources
Investment Thesis

A16z Bio invests in transformative life sciences companies that leverage technology to radically improve human health. They focus on companies at the intersection of biology, computation, and engineering that can scale breakthrough therapies and diagnostics.

Stage & Sector Focus

Primarily Series A to growth stage investments in biotech, digital health, and healthcare infrastructure. Heavy emphasis on AI-driven drug discovery, genomics, and companies with strong tech/data moats rather than traditional pharma plays.

Notable Portfolio
FreenomeMindstrong HealthDevoted HealthNurxBenchlingRecursion PharmaceuticalsInsitroColor
Key Partners
Julie Yoo
General Partner

Co-founder of Kyruus and previously at BCG. Known for deep healthcare ops expertise and helping portfolio companies navigate complex regulatory and go-to-market challenges. Founders praise her hands-on approach.

Vineeta Agarwala
General Partner

Former practicing physician and Google Product Manager. Brings rare combo of clinical experience and tech product sense. Known for being exceptionally founder-friendly and accessible.

Jorge Conde
General Partner

Former Flagship Pioneering partner with deep biotech investing experience. Strong track record in computational biology and drug discovery. Reputation for being tough but fair in diligence.

Have a specific question about Andreessen Horowitz Bio + Health?

Ask Bernie →
INVESTOR ACCESS PERMANENTLY DENIEDBERNBOOK // DOSSIER v1